Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Strata Critical Medical, Inc. (SRTA)

Healthcare Medical Care Facilities
5.00 $
-1.4% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Strata Critical Medical, Inc..

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 4 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet
Momentum & Trend
Risk & Weakness

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Trading Day

Previous Close
5.10$
Open
5.10$
Day High
5.20$
Day Low
4.90$
Volume
760,761shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
3.80 $ 6.50 $
08/07/2025 05/28/2026

Current price 5.00 $ — 44% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
0.0$B
Shares Outstanding
87Mio.
Float
66.3%
Beta
2.2

Performance

Perf. 1M
-19.90%
Perf. 3M
25.10%
Perf. 6M
4.00%
YTD Performance (%)
15.80%
52-Week-High Distance
-17.5%
Perf. 1Y
25.81%
Perf. 3Y
20.38%
Perf. 5Y
-34.55%
Perf. Since Inception
-48.51%

Technical Indicators

MA 38 Days
5.30$
MA 50 Days
5.50$
MA 200 Days
5.00$
RSI (14)
43.6
Volatility 30 Days
37.5%
Volatility 250 Days
61.4%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
138.9
PEG
P/B
1.6
P/S
EV/EBITDA
-9.9
Price/FCF

Profitability

Gross Margin
21.1%
EBIT Margin
Net Margin
20.6%
Return on Equity
-6.4%
Return on Assets
-1.9%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
0.02
fortress balance sheet
Altman Z″
10.72
Piotroski
6 out of 9

Growth

Sales Growth Last Quarter
0.00%
EPS Growth Last Quarter
Sales Growth (Year)
-20.73%
Forward Sales Growth
10.71%
Forward EPS Growth

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
RS Rating
65
EPS Rating
50
Piotroski
6 out of 9
Fundamental Rating
C (54 out of 100)
fortress balance sheet
Altman Z″
10.72

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 5.00 $
Price Target (average) 9.25 $

The price target sits 85.0% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

4. Aug 2026 · before the open · Q2 2026
Expected Earnings per Share
-0.04 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 54.4 $M Q4 2025: Q1 · 54.3 $M Q1 2025: Q2 · 70.8 $M Q2 2025: Q3 · 49.3 $M Q3 2025: Q4 · 66.8 $M Q4 2026: Q1 · 67.4 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.12 54 14.50 -18.00 0 -5
2025: Q1 -0.04 54 5.40 -6.40 -5 -8
2025: Q2 -0.05 71 4.20 -5.30 -4 -7
2025: Q3 0.70 49 -34.20 116.50 -32 -35
2025: Q4 -0.07 67 22.90 -8.10 -8 -10
2026: Q1 0.03 67 24.10 3.70 4 -2
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Strata Critical Medical, Inc. bietet zeitkritische Logistik- und medizinische Dienstleistungen für die Gesundheitsbranche in den USA an.

Employees327
HeadquartersNew York, NY
Websitestratacritical.com
IPO Date28. Aug 2025

Management

Management
Name Title Birth Year
Melissa M. Tomkiel J.D. Co- CEO, General Counsel, Corporate Secretary & Director 1981
William A. Heyburn Co-CEO, CFO & Director 1989
Amir M. Cohen Chief Accounting & Integration Officer 1977
Scott M. Wunsch Chief Executive Officer of Logistics Services 1977
Mathew Schneider C.F.A. CFO of Clinical Services & VP of Finance and Investor Relations
Keith Trepanier Chief of Safety
Louis R. Verdetto Chief Executive Officer of Clinical Services 1984
Scott Silvestry Chief Medical Officer

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?